# High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

> **NCT00747877** · PHASE3 · UNKNOWN · sponsor: **Leeds Cancer Centre at St. James's University Hospital** · enrollment: 460 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00747877
- **Lead sponsor:** Leeds Cancer Centre at St. James's University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2012-04
- **Final completion:** —
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747877, "High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00747877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*